Hair Loss Treatment & Side Effects: Infant Growth & Eye Risks

by Grace Chen

Summary of Article: Minoxidil Side Effects in Infants and Adults

this article details a new global safety study revealing unexpected side effects linked to minoxidil, a popular over-the-counter hair loss treatment.Here’s a breakdown of the key findings:

Key Concerns:

* Infantile Hypertrichosis (Excessive Hair Growth in Infants): The study found 2,664 global reports of this condition possibly linked to minoxidil exposure, with 45 cases involving children under two. 22.2% of these cases were linked to maternal exposure during pregnancy or breastfeeding.
* Serious Eye Disorders in Adults: (While not detailed in this excerpt, the article states this is also a finding of the study).
* Widespread, Unregulated Use: The easy availability of minoxidil without a prescription is a major concern, contributing to potential misuse and underreporting of side effects.

How Infants are Exposed:

* Maternal Exposure: Through breastmilk or during pregnancy.
* Accidental Exposure: Skin-to-skin contact with parents applying the treatment, or accidental ingestion.
* Unknown Sources: In roughly a third of cases, the source of exposure was unclear.

Why Infants are Vulnerable:

* Thinner Skin: Infants have thinner skin, leading to increased absorption of the drug.
* High absorption Capacity: Infants generally absorb substances more readily.
* Systemic Effects: Minoxidil’s mechanism of action (vasodilation and affecting potassium channels) can cause hair growth all over the body in infants,not just the scalp.

Important Note:

* Minoxidil is contraindicated (should not be used) in pregnant and breastfeeding women, but its accessibility and lack of awareness contribute to its use in these populations.
* Underreporting of cases is likely, especially in countries like India where the drug is widely available.

Source: The study was published in Archives of Dermatological Research and analyzed data from the World Health Institution’s global safety database, VigiBase, up to March 2025. Researchers from the Indian Pharmacopoeia Commission and All india Institute of Medical Sciences collaborated on the research.

You may also like

Leave a Comment